Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380079752> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4380079752 endingPage "503" @default.
- W4380079752 startingPage "503" @default.
- W4380079752 abstract "Background: Advanced-stage or relapsed/refractory (r/r) natural killer/T cell lymphoma (NKTCL) has a poor prognosis. The anti-programmed death 1 (PD-1) antibody has demonstrated satisfactory efficacy and good tolerance in treating r/r NKTCL. In this report, we present the interim analysis results of a prospective multicenter phase II study. Methods: Patients with advanced-stage or r/r NKTCL were eligible for participation. The DAPT regimen chemotherapy was administered as the protocol treatment, which included dexamethasone 10 mg on days 1–3, azacytidine 100 mg on days 1–5, pegaspargase 3750 IU on day 1, and tislelizumab 200 mg on day 6. Cycles were repeated every 21 days. The primary endpoint was the overall response rate (ORR) after the protocol treatment. Results: A total of 29 eligible patients were enrolled, with a median age of 52 years (range, 35 to 72 years) and a male-to-female ratio of 2.2:1. Eighteen patients had newly diagnosed disease with stage IV, while 11 had r/r disease. Among 21 patients with available response, the ORR and complete response rates were 76% and 33% for the entire cohort, 85% and 39% for newly diagnosed stage IV disease, and 63% and 25% for r/r disease, respectively. Six patients underwent autologous hematopoietic stem cell transplantation. The median progression-free survival was 10.7 months (range, 1.3–20.9 months). The most common adverse events were neutropenia (17%), elevated alanine aminotransferase (13%), and decreased fibrinogen (10%). No treatment-related deaths were observed. Conclusion: The DAPT regimen chemotherapy is an effective and tolerable treatment for advanced-stage or r/r NKTCL. The research was funded by: Clinical research fund for distinguished young scholars of Beijing Cancer Hospital (Grant No. QNJJ202106 Keywords: Aggressive T-cell non-Hodgkin lymphoma, Combination Therapies No conflicts of interests pertinent to the abstract." @default.
- W4380079752 created "2023-06-10" @default.
- W4380079752 creator A5001191342 @default.
- W4380079752 creator A5004358361 @default.
- W4380079752 creator A5005557322 @default.
- W4380079752 creator A5008929720 @default.
- W4380079752 creator A5013906441 @default.
- W4380079752 creator A5019659276 @default.
- W4380079752 creator A5042355911 @default.
- W4380079752 creator A5047036161 @default.
- W4380079752 creator A5048061116 @default.
- W4380079752 creator A5060540795 @default.
- W4380079752 creator A5062792807 @default.
- W4380079752 creator A5088240691 @default.
- W4380079752 date "2023-06-01" @default.
- W4380079752 modified "2023-10-13" @default.
- W4380079752 title "Interim analysis of a prospective multicenter phase II study for advanced‐stage or relapsed/refractory natural killer/T cell lymphoma" @default.
- W4380079752 doi "https://doi.org/10.1002/hon.3164_370" @default.
- W4380079752 hasPublicationYear "2023" @default.
- W4380079752 type Work @default.
- W4380079752 citedByCount "0" @default.
- W4380079752 crossrefType "journal-article" @default.
- W4380079752 hasAuthorship W4380079752A5001191342 @default.
- W4380079752 hasAuthorship W4380079752A5004358361 @default.
- W4380079752 hasAuthorship W4380079752A5005557322 @default.
- W4380079752 hasAuthorship W4380079752A5008929720 @default.
- W4380079752 hasAuthorship W4380079752A5013906441 @default.
- W4380079752 hasAuthorship W4380079752A5019659276 @default.
- W4380079752 hasAuthorship W4380079752A5042355911 @default.
- W4380079752 hasAuthorship W4380079752A5047036161 @default.
- W4380079752 hasAuthorship W4380079752A5048061116 @default.
- W4380079752 hasAuthorship W4380079752A5060540795 @default.
- W4380079752 hasAuthorship W4380079752A5062792807 @default.
- W4380079752 hasAuthorship W4380079752A5088240691 @default.
- W4380079752 hasBestOaLocation W43800797521 @default.
- W4380079752 hasConcept C126322002 @default.
- W4380079752 hasConcept C141071460 @default.
- W4380079752 hasConcept C188816634 @default.
- W4380079752 hasConcept C203092338 @default.
- W4380079752 hasConcept C2776694085 @default.
- W4380079752 hasConcept C2777063308 @default.
- W4380079752 hasConcept C2779338263 @default.
- W4380079752 hasConcept C2781413609 @default.
- W4380079752 hasConcept C535046627 @default.
- W4380079752 hasConcept C61943457 @default.
- W4380079752 hasConcept C71924100 @default.
- W4380079752 hasConcept C90924648 @default.
- W4380079752 hasConceptScore W4380079752C126322002 @default.
- W4380079752 hasConceptScore W4380079752C141071460 @default.
- W4380079752 hasConceptScore W4380079752C188816634 @default.
- W4380079752 hasConceptScore W4380079752C203092338 @default.
- W4380079752 hasConceptScore W4380079752C2776694085 @default.
- W4380079752 hasConceptScore W4380079752C2777063308 @default.
- W4380079752 hasConceptScore W4380079752C2779338263 @default.
- W4380079752 hasConceptScore W4380079752C2781413609 @default.
- W4380079752 hasConceptScore W4380079752C535046627 @default.
- W4380079752 hasConceptScore W4380079752C61943457 @default.
- W4380079752 hasConceptScore W4380079752C71924100 @default.
- W4380079752 hasConceptScore W4380079752C90924648 @default.
- W4380079752 hasIssue "S2" @default.
- W4380079752 hasLocation W43800797521 @default.
- W4380079752 hasOpenAccess W4380079752 @default.
- W4380079752 hasPrimaryLocation W43800797521 @default.
- W4380079752 hasRelatedWork W2062576298 @default.
- W4380079752 hasRelatedWork W2094558159 @default.
- W4380079752 hasRelatedWork W2169448488 @default.
- W4380079752 hasRelatedWork W2384274503 @default.
- W4380079752 hasRelatedWork W2680183591 @default.
- W4380079752 hasRelatedWork W2790917413 @default.
- W4380079752 hasRelatedWork W2981319632 @default.
- W4380079752 hasRelatedWork W2995411603 @default.
- W4380079752 hasRelatedWork W4224304085 @default.
- W4380079752 hasRelatedWork W4295837043 @default.
- W4380079752 hasVolume "41" @default.
- W4380079752 isParatext "false" @default.
- W4380079752 isRetracted "false" @default.
- W4380079752 workType "article" @default.